Imagine a typo hidden in your genome. One letter out of three billion. It causes you no harm — you are healthy, no symptoms, no limitations. But if your partner carries the exact same typo in the same gene, your child has a 25 per cent chance of inheriting two defective versions — and then the typo becomes a disease.
This is carrier status. Not a disease, not a sentence, not a rarity. According to the European Society of Human Genetics, every person carries on average two to three recessive mutations capable of causing serious disease in a child, if the other parent carries the same variant. Most of us have no idea. Most will never find out — unless their partner happens to carry the same variant.
Most genetic diseases discussed in the context of carrier screening are recessive. This means: for the disease to appear, a child must inherit the defective gene variant from both parents. If only one parent is a carrier, the child is either completely unaffected (50% probability) or becomes a carrier themselves (50%) — but does not get sick.
If both parents carry the same variant: a 25% chance the child inherits both defective copies and is affected; a 50% chance of carrier status without disease; a 25% chance the child inherits neither defective copy. The mathematics is ruthless precisely because it is neutral. No family history of disease, no visible signs — just a probability that can be known in advance. Or not.
Cystic fibrosis — severe lung and digestive disease. Carrier frequency in Northern and Western Europe: approximately 1 in 25. In Ireland — one of the highest rates in the world: 1 in 19. In Israel, among Ashkenazi Jews: 1 in 29; lower in other Jewish communities.
Spinal muscular atrophy (SMA) — progressive loss of muscle control. Before gene therapy (Zolgensma, approved by the FDA in 2019, the EMA in 2020), severe SMA was the leading genetic cause of infant death worldwide. Carrier frequency: 1 in 40–50 in European populations.
Sickle cell disease — common primarily among people of African, Middle Eastern, Mediterranean and South Asian descent. In some West African populations, 1 in 4 is a carrier. In Europe, most relevant to immigrant communities.
Tay-Sachs disease — a severe neurodegenerative condition incompatible with survival beyond a few years. Among Ashkenazi Jews: 1 in 30 carriers; in French-Canadian and Cajun populations: comparably elevated. In other populations: considerably rarer.
Phenylketonuria (PKU) — a metabolic disorder manageable with diet, but requiring early identification. One of the rare cases where newborn screening (heel-prick blood test) can prevent all consequences — but only if diagnosed within the first days of life.
Why carriers are healthy — and what evolution has to do with it
If a mutation is so dangerous, why hasn't it disappeared from the population? Part of the answer lies in the phenomenon of heterozygote advantage. Carriers of sickle cell disease historically survived malaria better — one defective copy of the HBB gene offered partial protection without causing disease. This explains why the mutation is so widespread in malaria-endemic regions.
A similar hypothesis exists for cystic fibrosis: carriers may have been better protected against certain infectious diseases, including cholera. Evolution does not optimise for the distant future — it selects what works here and now. The result: mutations that are lethal in double dose are widely distributed in the population in single dose, because in single dose they are either neutral or even beneficial.
Carrier screening is a DNA analysis (saliva or blood) that checks for known pathogenic variants in genes associated with recessive diseases. A basic panel covers 3 to 5 conditions. An expanded one covers hundreds. Expanded carrier screening (ECS) tests simultaneously for 100 to 500 or more genetic conditions — depending on the laboratory and panel.
The test cannot cover every possible variant — the genome is too complex. It checks the most clinically significant and well-studied ones. A negative result reduces risk, but does not eliminate it entirely. This is a probabilistic tool, not a guarantee.
The optimal time is before conception. This gives the maximum range of options: if both partners turn out to be carriers of the same variant, the couple can consider IVF with preimplantation genetic testing (PGT), which allows selection of embryos without defective variants; egg or sperm donation; prenatal diagnosis during an existing pregnancy; or an informed acceptance of risk with psychological support.
Screening is relevant for everyone — regardless of family history. The majority of children with genetic diseases are born into families with no prior history of illness. Precisely because carriers are healthy and never knew their status. Particularly recommended when: using donor sperm or eggs (the donor should be screened — and many licensed banks require this); planning co-parenting (genetic compatibility is one of the first questions to clarify); or in consanguineous relationships — the risk of matching recessive variants is substantially higher.
Most people who undergo carrier screening receive a negative result across all tested variants — or discover carrier status for one condition without any risk to a child (if the partner is not a carrier of the same variant). This is not a crisis. It is simply information.
If both partners turn out to be carriers — this is the point for a consultation with a clinical geneticist. The specialist will explain the actual risks in the specific case, discuss options and help make a decision with full understanding of all possibilities. This is not the end of the conversation about parenthood. It is the beginning of an informed one.
Carrier screening is not looking for disease. It is looking for information that allows reproductive decisions to be made with open eyes. Most carriers never encounter the disease in their families. But knowing your status before conception means having a choice that would otherwise simply not exist.